Essential Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Essential Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$187K	Sell	3,115 -16	-0.5%	-$1.01K	0.09%	259
2026 Q2	$179K	Sell	3,131 -5,646	-64%	-$309K	0.08%	260
2026 Q1	$496K	Sell	8,777 -8,843	-50%	-$516K	0.17%	149
2025 Q4	$1.05M	Buy	17,620 +3,400	+24%	+$185K	0.32%	83
2025 Q3	$770K	Sell	14,220 -4,105	-22%	-$235K	0.25%	107
2025 Q2	$1.01M	Buy	+18,325	New	+$1.08M	0.4%	61

Other funds holding BMRN

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

FFBTD

First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

MGI

Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

Essential Partners's BMRN Position: Q3 2026 in Review

Essential Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.51% in Q3 2026, selling an estimated $1.01K and leaving 3,115 shares worth $187K. The position accounts for 0.09% of the portfolio, ranked #259.

Essential Partners first reported a position in BMRN in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.05M in Q4 2025. 29 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Essential Partners held 3,115 shares of BioMarin Pharmaceuticals worth $187K as of Q3 2026.
Essential Partners sold 16 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $1.01K.
BioMarin Pharmaceuticals made up 0.09% of Essential Partners's portfolio in Q3 2026, its #259 holding.
Essential Partners first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Essential Partners's BioMarin Pharmaceuticals position peaked at $1.05M in Q4 2025.
29 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.